Repository logo
 

C5a anaphylatoxin and its role in critical illness-induced organ dysfunction.

Simple item page
cam.issuedOnline2018-10-15
dc.contributor.authorWood, Alexander JT
dc.contributor.authorVassallo, Arlette
dc.contributor.authorSummers, Charlotte
dc.contributor.authorChilvers, Edwin R
dc.contributor.authorConway-Morris, Andrew
dc.contributor.orcidWood, Alexander JT [0000-0001-7819-0447]
dc.contributor.orcidSummers, Charlotte [0000-0002-7269-2873]
dc.contributor.orcidChilvers, Edwin R [0000-0002-4230-9677]
dc.contributor.orcidConway-Morris, Andrew [0000-0002-3211-3216]
dc.date.accessioned2018-11-20T00:31:40Z
dc.date.available2018-11-20T00:31:40Z
dc.date.issued2018-12
dc.description.abstractCritical illness is an aetiologically and clinically heterogeneous syndrome that is characterised by organ failure and immune dysfunction. Mortality in critically ill patients is driven by inflammation-associated organ damage and a profound vulnerability to nosocomial infection. Both factors are influenced by the activated complement protein C5a, released by unbridled activation of the complement system during critical illness. C5a exerts deleterious effects on organ systems directly and suppresses antimicrobial functions of key immune cells. Whilst several recent reports have added key knowledge of the cellular signalling pathways triggered by C5a, there remain a number of areas that are incompletely understood and therapeutic opportunities are still being evaluated. In this review, we summarise the cellular basis for C5a-induced vulnerability to nosocomial infection and organ dysfunction. We focus on cells of the innate immune system, highlighting the major areas in need of further research and potential avenues for targeted therapies.
dc.description.sponsorshipGates Cambridge Trust NIHR Cambridge Biomedical Research Centre
dc.format.mediumPrint-Electronic
dc.identifier.doi10.17863/CAM.32842
dc.identifier.eissn1365-2362
dc.identifier.issn0014-2972
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/285484
dc.languageeng
dc.language.isoeng
dc.publisherWiley
dc.publisher.urlhttp://dx.doi.org/10.1111/eci.13028
dc.subjectC5a
dc.subjectcomplement
dc.subjectcritical illness
dc.subjectimmunosuppression
dc.subjectinfection
dc.subjectneutrophil
dc.subjectAnaphylatoxins
dc.subjectBlood Coagulation
dc.subjectBlood Platelets
dc.subjectCardiovascular System
dc.subjectCell Communication
dc.subjectComplement C5a
dc.subjectCritical Illness
dc.subjectEndothelium, Vascular
dc.subjectHumans
dc.subjectImmune System Diseases
dc.subjectImmunity, Innate
dc.subjectMultiple Organ Failure
dc.subjectReceptor, Anaphylatoxin C5a
dc.titleC5a anaphylatoxin and its role in critical illness-induced organ dysfunction.
dc.typeArticle
dcterms.dateAccepted2018-09-11
prism.issueIdentifier12
prism.publicationDate2018
prism.publicationNameEur J Clin Invest
prism.startingPagee13028
prism.volume48
pubs.funder-project-idEuropean Society of Intensive Care Medicine (ESICM) (unknown)
pubs.funder-project-idAcademy of Medical Sciences (unknown)
pubs.funder-project-idWellcome Trust (205214/Z/16/Z)
pubs.funder-project-idMRC (MC_PC_17208)
rioxxterms.licenseref.startdate2018-12
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.typeJournal Article/Review
rioxxterms.versionAM
rioxxterms.versionofrecord10.1111/eci.13028

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
EJCI C5a review final for resubmission (2).docx
Size:
761.9 KB
Format:
Microsoft Word XML
Description:
Accepted version
Licence
http://www.rioxx.net/licenses/all-rights-reserved
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
DepositLicenceAgreementv2.1.pdf
Size:
150.9 KB
Format:
Adobe Portable Document Format
Download

Collections

Cambridge University Research Outputs